Cytokeratin 12 Inhibitors
The chemical class of Cytokeratin 12 inhibitors encompasses a diverse range of compounds designed to either directly inhibit or indirectly modulate the expression and function of Cytokeratin 12. Among these inhibitors are Sorafenib, SB203580, LY294002, U0126, Rapamycin, SP600125, Wortmannin, PD98059, SP2509, AZD8055, VX-745, and sc-514. While some of these compounds act by directly targeting Cytokeratin 12, others exert their effects indirectly by influencing key signaling pathways involved in its regulation. Sorafenib, a multi-kinase inhibitor, operates indirectly by modulating the RAF/MEK/ERK signaling pathway. This modulation induces alterations in downstream events, leading to changes in cellular processes that subsequently affect Cytokeratin 12 expression and activity. Similarly, SB203580, a p38 MAPK inhibitor, indirectly modulates Cytokeratin 12 by affecting the p38 MAPK signaling pathway. The impact on this pathway alters the cellular response to stimuli, indirectly influencing Cytokeratin 12 expression in specific cellular contexts.
The compounds LY294002, U0126, Rapamycin, SP600125, Wortmannin, PD98059, SP2509, AZD8055, VX-745, and sc-514 act through various signaling pathways, including PI3K/AKT, MAPK/ERK, mTOR, JNK, HDAC, and NF-κB. These pathways are intricately involved in cellular processes, and the inhibitors modulate them to indirectly influence Cytokeratin 12 in specific cellular contexts. This diverse array of inhibitors provides valuable tools for researchers aiming to dissect the intricate regulatory mechanisms governing Cytokeratin 12 and its multifaceted role in cellular physiology. The chemical class of Cytokeratin 12 inhibitors not only serves as a valuable resource for investigating the intricacies of Cytokeratin 12 modulation but also contributes significantly to our understanding of the broader regulatory networks within which Cytokeratin 12 operates. Researchers can leverage these inhibitors to explore the multifaceted role of Cytokeratin 12 in cellular physiology, shedding light on its involvement in various signaling pathways and cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly influences Cytokeratin 12 through modulation of the RAF/MEK/ERK signaling pathway. By inhibiting RAF kinases, it disrupts downstream signaling events, leading to alterations in cellular processes that indirectly impact Cytokeratin 12 expression and activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly modulates Cytokeratin 12 by affecting the p38 MAPK signaling pathway. Its inhibition of p38 MAPK alters the cellular response to various stimuli, indirectly influencing the expression and function of Cytokeratin 12 in specific cellular contexts. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly influences Cytokeratin 12 by targeting the JNK signaling pathway. Through the inhibition of JNK, SP600125 disrupts downstream events, leading to indirect modulation of Cytokeratin 12 expression and function in specific cellular contexts. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly impacts Cytokeratin 12 by inhibiting the PI3K signaling pathway. Through disruption of PI3K, Wortmannin alters downstream events, leading to indirect modulation of Cytokeratin 12 expression and function in specific cellular contexts. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly influences Cytokeratin 12 through the inhibition of the MAPK/ERK signaling pathway. By targeting MEK, PD98059 disrupts downstream events, leading to indirect modulation of Cytokeratin 12 expression and function in specific cellular contexts. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509, a HDAC inhibitor, indirectly modulates Cytokeratin 12 expression and function by influencing histone deacetylation processes. Through the inhibition of HDAC, SP2509 alters the epigenetic landscape, leading to indirect effects on Cytokeratin 12 in specific cellular contexts. | ||||||
AZD2014 | 1009298-59-2 | sc-364420 | 5 mg | $303.00 | 2 | |
AZD8055, an mTOR inhibitor, indirectly influences Cytokeratin 12 through the inhibition of the mTOR signaling pathway. Its impact on mTOR signaling alters downstream processes, leading to indirect modulation of Cytokeratin 12 expression and function in specific cellular contexts. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745, a p38 MAPK inhibitor, indirectly modulates Cytokeratin 12 by affecting the p38 MAPK signaling pathway. Its inhibition of p38 MAPK alters the cellular response to various stimuli, indirectly influencing the expression and function of Cytokeratin 12 in specific cellular contexts. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
SC-514, an IKK-2 inhibitor, indirectly impacts Cytokeratin 12 by modulating the NF-κB signaling pathway. Through the inhibition of IKK-2, SC-514 disrupts downstream events, leading to indirect modulation of Cytokeratin 12 expression and function in specific cellular contexts. | ||||||